THERAPY DOSSIER · th-6a3299d34efd

Pentacaine

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 3394576 ↗1988Reported benefit

Gastroprotective effect of pentacaine: role of mast cells.

RatChemical/toxinInbred strain not specifiedFemaleDose-dependent protection reported; specific doses not stat…Before ethanol exposure

Model: Acute haemorrhagic gastric lesions induced by ethanol

Pentacaine dose-dependently prevented ethanol-induced acute haemorrhagic gastric lesions. Untreated rats showed extensive surface epithelial disruption, deep mucosal necrosis, mast cell degranulation or destruction and microvascular derangement, all of which were absent after pentacaine treatment.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…